Related Experiment Videos

Factor VIIa levels are decreased in patients with hemophilia B

J Matsuda, N Saitoh, K Gohchi

American Journal of Hematology

|February 1, 1994

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.

Journal of thrombosis and haemostasis : JTH·2016

Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2015

Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.

Journal of thrombosis and haemostasis : JTH·2014

A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.

Haemophilia : the official journal of the World Federation of Hemophilia·2013

See all related articles